N/A N=20 Standard Post Market Clinical Follow-up (PMCF) Study WSA @ HZO
Hearing Loss, Sensorineural
Primary: Oldenburg Sentence Test — -6.6; -1.1; -3.5 dB — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=55 Epione® Post-Market Clinical Follow-up Study
Cancer Abdomen
Primary: Technical Success — 50 Participants
N/A N=150 Avenir Müller Hip Stem Post Market Surveillance Study
Osteoarthritis, Hip · Rheumatoid Arthritis · Fracture of Hip
Primary: Evaluation of Pain and Functional Performance Determined by the Harris Hip Score — 90.9 score on a scale
Phase 4 N=60 Post Market Clinical Follow-up Study
Hip or Knee Surgery
Primary: Minimize the Risk of the Development of Blistering. — 60 participants
N/A N=5 Post-Market Clinical Follow Up Study to Collect Additional Data and Imaging
Connective Tissue Defect
Primary: # of Subjects With Altered Gene Expression — 4 Participants
N/A N=106 Multi Centre Study on TESS V2 Shoulder System
Osteoarthritis Shoulder · Fracture · Rheumatoid Arthritis
Primary: Constant Shoulder Score — 27.36; 63.5 score on a scale
N/A N=321 CardioMEMS HF System OUS Post Market Study
Heart Failure · Left-Sided Heart Failure · Congestive Heart Failure
Primary: Freedom From Device/System Related Complications — 304 Participants
N/A N=100 Medtronic HAMMOCK Post Approval Study
Heart Valve Diseases
Primary: Number of Deaths, Reinterventions, or Explants — 2; 0 Participants
N/A N=620 Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
Gastrointestinal Stromal Tumors
Primary: Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), Unexpected AEs/ADRs, and Unexpected…
N/A N=47 X-Seal EU Post-Market Clinical Follow-Up Protocol
Femoral Arteriotomy Closure
Primary: Major Complications — 0; 0 Participants
N/A N=142 Ellipsys Vascular Access System Post Market Surveillance (PS) Study
Renal Disease, End Stage · Kidney Disease, End-Stage · AV Fistula
Primary: Cumulative Patency Through 12 Months Post-AVF Creation — 99.1 Probability as a percentage
N/A N=10 Post Market Clinical Follow Up Study of Avance Foam Abdominal Dressing Kit in Open Abdomen
Open Abdomen
Primary: To Evaluate the Performance of the Dressing Kit as Part of a Negative Pressure System in Post Market Clinical Follow-up Settings — 4; 3; 2; 1 number of surgeons
N/A N=110 InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Overactive Bladder · Urinary Urge Incontinence · Urgency-frequency Syndrome
Primary: Motor or Sensory Response(s) During Lead Placement - by Subject — 107; 109; 3; 1 Participants
N/A N=1,064 RESPOND Post Market Study
Aortic Valve Stenosis
Primary: All-cause Mortality — 26; 0 Participants — p=<.0001
N/A N=50 BioFiber Scaffold Post-Market Observational Study
Full Thickness Rotator Cuff Tear
Primary: Number of Participants With Device Associated Adverse Events — 4 Participants
N/A N=25 PMCF Study on CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures
Skull Fractures
Primary: Planarity of Bone Flap After Implantation — 23; 0; 2; 17 Participants
N/A N=649 Prevenar13 Post Market Surveillance
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Within 7 Days After Vaccination 1 — 68; 1 participants
N/A N=362 Post Marketing Surveillance Study For Sayana®
Product Surveillance, Postmarketing
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 81; 1 Participants
N/A N=100 Duragen® Secure Post Marketing Clinical Follow-up (PMCF)
Dura Mater Nick Cut or Tear · Surgery
Primary: Patient's Outcome — 73; 7; 15; 3 Participants
N/A N=180 Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
Glioblastoma
Primary: Median Progression Free Survival After Primary Surgical Treatment, Concomitant and Adjuvant Chemotherapy With Temozolomide, for Patients With Newly Diagnosed…
N/A N=53 Post Approval Study of the remedē System
Central Sleep Apnea
Primary: 5-Year Survival Rate — 78 percentage of participants
N/A N=145 Post Market Study of Parietene™ DS Composite Mesh in Ventral Hernia Repair
Ventral Hernia
Primary: Number of Participants With Hernia Recurrence Within 12 Months Following Parietene™ DS Composite Mesh Use in Ventral Hernia Repair — 4; 116 Participants
N/A N=107 Post Market Study of the InnFocus MicroShunt
Primary Open Angle Glaucoma
Primary: Number of Participants With Study Success — 62; 59; 58; 60 Participants
N/A N=39 Melody PB1016 Surveillance Study
Dysfunctional RVOT Conduits in Patients With Congenital Heart Defects
Primary: Number of Subjects With Acceptable TPV Hemodynamic Function At 6 Months — 25 Participants
N/A N=44,456 Post-marketing Surveillance Study for Evaluation of Dotarem Safety
Contrast-enhanced MRI With Dotarem
Primary: Frequency of Adverse Events — 225 adverse events
N/A N=65 Post-market Clinical Study to Confirm Safety and Performance of PuraStat® for the Management of Bleeding in Vascular Surgery.
Vascular Anastomosis Surgery
Primary: Total Time-To-Haemostasis — 83 Secondes
N/A N=126 NeoChord TACT Post-Market Surveillance Registry
Mitral Valve Insufficiency · Heart Valve Diseases · Heart Diseases
Primary: Procedure Success — 121; 5 Participants
N/A N=167 Master Study of the BIOMONITOR III and Incision and Insertion Tool (FIT OneStep)
Tachyarrhythmia · Atrial Fibrillation (AF) · Syncope
Primary: SADE-free Rate Until the 3-month Follow-up — 141 Participants — p=0.05
N/A N=44 Post Market Study Using the Xoft Axxent System
Breast Cancer
Primary: Number of Participants With Delivery of 34 Gy in 10 Fractions — 42 Participants
N/A N=124 Ambispective, Multicentre, Open-label Study Evaluating the Clinical Outcomes of Foot Surgery Using SERF Medical Devices
Foot Diseases
Primary: Reduction of the Patient's Pain and Restoration of Walking — 42.46; 88.44 points